Now to the ongoing chatter. For a while, ULGX onlookers have been mentioning, perhaps hoping for, a takeover. Rightfully so, in my opinion. Given that last month Boston Scientific ( BSX ) completed a $60 million purchase of a competing prostate treatment product line, Prolieve, from Celsion Corporation (CLN), there is added economic pressure for ULGX to join forces with another company. Granted, prior to the purchase, BSX was the exclusive distributor of Prolieve, and, in fact, owned about 8% of CLN's common stock. So, it is not exactly a new competitor to the sector, just a more formidable one.